Precision medicine advances in idiopathic pulmonary fibrosis

作者：Τheodoros Karampitsakos, Brenda Juan-Guardela, Argyris Tzouvelekis, Jose D. Herazo‐Maya · 发表于：EBioMedicine · 年份：2023 · DOI：10.1016/j.ebiom.2023.104766 · 被引用次数：151 · 研究领域：Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis、Occupational and environmental lung diseases、Lung Cancer Treatments and Mutations

Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous, unpredictable and ultimately lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown to slow disease progression, however, both drugs are administered uniformly with minimal consideration of disease severity and inter-individual molecular, genetic, and genomic differences. Advances in biological understanding of disease endotyping and the emergence of precision medicine have shown that "a one-size-fits-all approach" to the management of chronic lung diseases is no longer appropriate. While precision medicine approaches have revolutionized the management of other diseases such as lung cancer and asthma, the implementation of precision medicine in IPF clinical practice remains an unmet need despite several reports demonstrating a large number of diagnostic, prognostic and theragnostic biomarker candidates in IPF. This review article aims to summarize our current knowledge of precision medicine in IPF and highlight barriers to translate these research findings into clinical practice.